PCOS and Long-Term Health: What Happens If It's Left Untreated

PCOS is widely understood as a condition that causes irregular periods and fertility problems. What is far less widely understood — by patients and often by primary care doctors — is that PCOS is a lifelong metabolic disorder whose consequences extend well beyond the reproductive years. For many women, the reproductive symptoms of PCOS diminish with age, creating the impression that the condition has resolved. It has not. The metabolic engine driving it continues to run, and without active management, it produces progressively serious long-term health consequences.

Type 2 Diabetes: The Most Important Long-Term Risk

Women with PCOS have a 5 to 10-fold increased lifetime risk of developing type 2 diabetes compared to age-matched women without PCOS. This risk is driven by the insulin resistance that underlies most PCOS — and it begins accumulating decades before diabetes becomes clinically apparent.

Studies following women with PCOS over decades show:

• Up to 40% of women with PCOS will have impaired glucose tolerance or type 2 diabetes by the age of 40
• Progression from normal glucose metabolism to impaired glucose tolerance to type 2 diabetes can occur over 5 to 10 years without lifestyle or medical intervention
• Pregnancy with PCOS significantly elevates gestational diabetes risk — and gestational diabetes is itself a major risk factor for postpartum type 2 diabetes

Prevention requires active management — lifestyle modification addressing insulin resistance, metformin where indicated, and regular monitoring. An oral glucose tolerance test (OGTT) every 1 to 3 years is recommended for all women with PCOS throughout their reproductive years and beyond.

Cardiovascular Disease

The cluster of metabolic features in PCOS — insulin resistance, elevated androgens, dyslipidaemia, hypertension, and central obesity — creates a significantly elevated cardiovascular risk profile. Specific findings in women with PCOS:

• Higher rates of LDL cholesterol elevation and low HDL cholesterol — the dyslipidaemia pattern associated with insulin resistance
• Elevated triglycerides
• Increased arterial stiffness and carotid intima-media thickness (a marker of early atherosclerosis) — detectable even in young women with PCOS
• Higher rates of hypertension (elevated blood pressure)
• Increased rates of subclinical cardiovascular disease markers at earlier ages than women without PCOS

The cardiovascular risk in PCOS is not just a theoretical concern — longitudinal studies show elevated rates of cardiovascular events in postmenopausal women with a history of PCOS. Annual blood pressure monitoring, lipid panel, and diabetes screening are appropriate for all adult women with PCOS.

Endometrial Cancer Risk

Women with chronic anovulation — absent or very infrequent ovulation — are exposed to continued oestrogen production from the ovaries and from peripheral fat tissue without the opposing effect of progesterone, which normally accompanies ovulation in the second half of the cycle. This "unopposed oestrogen" state causes progressive thickening of the uterine lining (endometrial hyperplasia), which — if untreated over years — can progress to endometrial cancer.

The risk is real and significant: women with PCOS who have chronic anovulation have approximately 3 times the lifetime risk of endometrial cancer compared to regularly ovulating women. Prevention is straightforward: ensuring regular progesterone exposure to the endometrium — either through restored ovulation, combined oral contraceptive pills, or cyclical progesterone. Women with PCOS who are not trying to conceive and are not on hormonal contraception need regular progestogen administration (at minimum every 3 to 4 months) to protect the endometrium. This is a point that is frequently missed in PCOS management.

Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD — the accumulation of fat in the liver in the absence of significant alcohol use — is significantly more common in women with PCOS than in age-matched controls. The underlying driver is insulin resistance and associated dyslipidaemia. NAFLD, if progressive (developing into non-alcoholic steatohepatitis — NASH), can lead to cirrhosis and liver failure over decades.

Annual liver enzyme monitoring (ALT, AST) and periodic liver ultrasound are appropriate for women with PCOS and significant insulin resistance, particularly those with central obesity.

Mental Health

Rates of depression, anxiety, eating disorders, and psychological distress are significantly elevated in women with PCOS — approximately 2 to 3 times higher than in women without PCOS. The drivers are multiple: the direct neurobiological effects of hormonal imbalance, the psychological burden of visible symptoms (acne, hirsutism, weight changes), fertility concerns, and the chronic nature of the condition. Mental health assessment and support should be integrated into PCOS management — it is not a peripheral concern.

Sleep Apnoea

Obstructive sleep apnoea is significantly more common in women with PCOS than in age-matched controls — even after adjusting for BMI. The mechanism involves both the structural effects of obesity (where present) and the independent effects of elevated androgens on upper airway muscle tone. Sleep apnoea amplifies insulin resistance and cardiovascular risk. Women with PCOS who report excessive daytime sleepiness, snoring, or unrefreshing sleep should be screened.

Managing Long-Term PCOS Health: A Framework

Long-term PCOS management requires ongoing monitoring beyond the reproductive years:

• Annual: Blood pressure, fasting glucose and insulin (or OGTT if previous impaired glucose tolerance), lipid panel, liver enzymes, weight and waist circumference
• Every 3 to 4 months (if anovulatory and not on hormonal contraception): Progestogen withdrawal bleed to protect the endometrium
• Periodic: Mental health assessment, sleep apnoea screening if relevant symptoms
• Lifestyle: Continued dietary management of insulin resistance and regular exercise — the most powerful long-term PCOS management tools available

Frequently Asked Questions

Q1. Does PCOS improve after menopause?

The androgenic and reproductive symptoms of PCOS typically diminish after menopause as ovarian androgen production falls. However, the metabolic consequences — insulin resistance, diabetes risk, cardiovascular risk — do not resolve with menopause. In fact, the protective effect of oestrogen on cardiovascular health is lost at menopause, and women with a history of PCOS may be at particularly elevated cardiovascular risk in the postmenopausal period.

Q2. If I am slim and my periods are regular, do I still need long-term monitoring?

Yes — even lean women with PCOS can have underlying insulin resistance and are at elevated metabolic risk relative to women without PCOS, though the absolute risk is lower than in overweight PCOS. If your cycles are regular (meaning you are ovulating), the endometrial cancer risk is substantially mitigated. But diabetes, cardiovascular, and mental health monitoring remain relevant.

Q3. Will my daughter have PCOS?

Your daughter's risk of PCOS is significantly higher than the general population risk. PCOS is heritable — daughters of women with PCOS have approximately a 35 to 50% probability of developing the condition. This does not mean she will definitely have it, but it means vigilance is warranted — monitoring her menstrual regularity from adolescence and seeking early investigation if irregular cycles emerge.